⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ZYME News
Zymeworks Inc.
Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer
globenewswire.com
ZYME
Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets
globenewswire.com
ZYME
Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma
globenewswire.com
ZYME
Zymeworks Provides Corporate Update and Reports Third Quarter 2025 Financial Results
globenewswire.com
ZYME
Zymeworks Announces Participation in Upcoming Investor Conferences
globenewswire.com
ZYME
Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference
globenewswire.com
ZYME
Zymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025
globenewswire.com
ZYME
Next-Generation Targeted Therapies Reshape Precision Oncology Landscape
prnewswire.com
GTBP
IDYA
ZYME
NVS
REGN
GTBP
IDYA
ZYME
NVS
REGN
Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference
globenewswire.com
ZYME
Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer
globenewswire.com
ZYME